Receptor News and Research

RSS

Women treated with breast cancer drugs can ease joint pain by engaging in exercise

Women being treated with breast cancer drugs known as aromatase inhibitors can markedly ease the joint pain associated with the drugs by engaging in moderate daily exercise, Dana-Farber Cancer Institute and Yale University investigators report in a study to be presented during the San Antonio Breast Cancer Symposium.

13 Dec 2013

Z-endoxifen may provide better treatment for women with estrogen positive breast cancer

A Phase I trial of endoxifen, an active metabolite of the cancer drug tamoxifen, indicates that the experimental drug is safe, with early evidence for anti-tumor activity, a Mayo Clinic study has found. The findings indicate that Z-endoxifen, co-developed by Mayo Clinic Cancer Center and the National Cancer Institute, may provide a new and better treatment for some women with estrogen positive breast cancer and, in particular, for those women who do not respond to tamoxifen and aromatase inhibitors.

13 Dec 2013

Anastrozole drug: An effective new option for breast cancer prevention for postmenopausal women

Breast cancer incidence among postmenopausal women at high risk for developing the disease was significantly reduced by the antihormone therapy anastrozole, indicating that the drug may be an effective new option for breast cancer prevention for this group of women, according to initial results of a double-blind, randomized, placebo-controlled trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. The study is being simultaneously published in the The Lancet.

13 Dec 2013

New treatment needed for women with HER2- and hormone receptor-positive breast cancer with PIK3CA mutation

Women with breast cancer characterized by high levels of the protein HER2 and hormone receptors gained much less benefit from presurgery treatment with chemotherapy and HER2-targeted therapies if their cancer had one or more mutations in the PIK3CA gene, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

12 Dec 2013

RBCC, Therakine reach major milestone in the development of new drug delivery technology

Rainbow Coral Corp. and its joint venture partner, Therakine, Ltd., are pleased to announce that they have reached a major new milestone in the development of a revolutionary new drug delivery technology.

12 Dec 2013

Combination therapy safe and active in follicular lymphoma

One drug attacks tumor cells directly, the other treats the immune system by taking the brakes off T cell response.

12 Dec 2013

New reports demonstrate the effectiveness of modified T cells in treating blood-borne cancers

At the 2013 American Society of Hematology meeting in Dec. 2013, James Kochenderfer, M.D., investigator in the Experimental Transplantation and Immunology Branch, NCI, presented findings from two clinical trials evaluating the use of genetically modified immune system T cells as cancer therapy.

12 Dec 2013

Study: Taxol and Herceptin highly effective for lower-risk breast cancer patients

A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.

12 Dec 2013

New test to help physicians identify patients with most lethal forms of triple-negative breast cancer

A new test has the potential to help physicians identify patients with the most lethal forms of triple-negative breast cancer, a disease which requires aggressive and innovative treatment.

12 Dec 2013

Johns Hopkins researchers use lung cancer drug to shrink chordoma in mice

Johns Hopkins researchers say that a drug approved to treat lung cancer substantially shrank tumors in mice that were caused by a rare form of bone cancer called chordoma.

12 Dec 2013

Early tumor shrinkage predicts targeted therapy efficacy in RCC

Early tumor shrinkage in patients with metastatic renal cell carcinoma following vascular endothelial growth factor-targeted therapy may herald good long-term survival, research shows.

11 Dec 2013

Acid-inhibiting medications linked with increased risk for vitamin B12 deficiency

Use for 2 or more years of proton pump inhibitors and histamine 2 receptor antagonists (two types of acid-inhibiting medications) was associated with a subsequent new diagnosis of vitamin B12 deficiency, according to a study appearing in the December 11 issue of JAMA.

11 Dec 2013

New research reveals novel way to develop anti-diarrhoeal drugs

New gastroenterology research carried out by the RCSI in conjunction with Trinity College Dublin and Johns Hopkins University in Baltimore, Maryland has uncovered a new route for the development of anti-diarrhoeal drugs.

11 Dec 2013

Experimental compound reduces joint inflammation in animal models of rheumatoid arthritis

An experimental compound synthesized and developed by scientists from the Florida campus of The Scripps Research Institute has the capacity to significantly reduce joint inflammation in animal models of rheumatoid arthritis, an autoimmune disease that affects more than two million Americans.

11 Dec 2013

Otsuka, Lundbeck to develop investigational vaccine candidate for Alzheimer's disease

H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that they will further expand their collaboration to include the development of Lu AF20513, an investigational vaccine candidate for Alzheimer's disease.

11 Dec 2013

Study links vitamin B12 deficiency to acid-suppressing medications

Long-term use of commonly prescribed heartburn and ulcer medications is linked to a higher risk of vitamin B12 deficiency, according to a new study published online in the Journal of the American Medical Association.

10 Dec 2013

Biosimulation and epilepsy treatments: an interview with Dr. Serge Bischoff, CEO of Rhenovia and RHENEPI program director

The need for biosimulation is primarily to do with the very high attrition rate in drug development and especially in the development of drugs for the central nervous system.

10 Dec 2013

Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation

Bone homeostasis requires precise balance between deposition of new bone by osteoblasts and resorption of old bone by osteoclasts. Bone diseases, including osteoporosis and rheumatoid arthritis, are the result of increased osteoclast activity and formation, which allows bone resorption to outpace deposition.

9 Dec 2013

Novel multi-kinase inhibitor shows early promise in NSCLC

Researchers have reported promising early data on an investigational drug that targets two tyrosine kinase receptors that drive invasive growth and drug resistance in non-small-cell lung cancer.

9 Dec 2013

Adocia gets development and commercialization rights in nanotechnology for drug delivery

Adocia, a biotechnology company specializing in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, announces today the signature of an exclusive license agreement with the CNRS, the University Bordeaux I, the Institut Polytechnique de Bordeaux and Aquitaine Science Transfert.

9 Dec 2013

Receptor News and Research

Women treated with breast cancer drugs can ease joint pain by engaging in exercise

Z-endoxifen may provide better treatment for women with estrogen positive breast cancer

Anastrozole drug: An effective new option for breast cancer prevention for postmenopausal women

New treatment needed for women with HER2- and hormone receptor-positive breast cancer with PIK3CA mutation

RBCC, Therakine reach major milestone in the development of new drug delivery technology

Combination therapy safe and active in follicular lymphoma

New reports demonstrate the effectiveness of modified T cells in treating blood-borne cancers

Study: Taxol and Herceptin highly effective for lower-risk breast cancer patients

New test to help physicians identify patients with most lethal forms of triple-negative breast cancer

Johns Hopkins researchers use lung cancer drug to shrink chordoma in mice

Early tumor shrinkage predicts targeted therapy efficacy in RCC

Acid-inhibiting medications linked with increased risk for vitamin B12 deficiency

New research reveals novel way to develop anti-diarrhoeal drugs

Experimental compound reduces joint inflammation in animal models of rheumatoid arthritis

Otsuka, Lundbeck to develop investigational vaccine candidate for Alzheimer's disease

Study links vitamin B12 deficiency to acid-suppressing medications

Biosimulation and epilepsy treatments: an interview with Dr. Serge Bischoff, CEO of Rhenovia and RHENEPI program director

Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation

Novel multi-kinase inhibitor shows early promise in NSCLC

Adocia gets development and commercialization rights in nanotechnology for drug delivery

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News